Work at Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has led to the identification of heteroaromatic ring compounds acting as membrane-associated tyrosine-and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.